In this episode, healthcare analyst Arthur Wong discusses our expectations for the ratings on generic drug giant Teva, which is seeking to close its $40.5 billion acquisition of Allergan's generic business. Mr. Wong also fields investors' questions concerning the prospects for Teva's business side and its stance on acquisitions.